Global inflation risk, driven by factors like the Middle East conflict pushing oil prices to $112, could increase Amarin's operational costs for R&D, manufacturing, and distribution, and potentially impact prescription affordability for consumers.

US CPI inflation data releases directly affect Amarin's domestic operating expenses and potential pricing strategies within the significant U.S. market.

The broader healthcare policy and regulatory environment, including patent expirations and increasing generic competition for its main product, Vascepa, poses a significant ongoing risk to Amarin's revenue and market share.